← Russell 3000 cross-section

FENC FENNEC PHARMACEUTICALS INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$410m
Revenue TTM
$59m
Net income TTM
$-3m
Free cash flow
Composite score
Sector rank
#2497

Valuation

P / E
EV / EBITDA
EV / sales
6.2
FCF yield
Earnings yield vs 10-yr
-5.51pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-5.5%
EBITDA margin
ROE
-7.7%
ROIC
-94.2%
Revenue growth
77.8%

Insider activity, last 90 days

Net open-market
$-1.17m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The year-over-year improvement was primarily driven by the shift from a net loss of $4,317 to net income of $2,174 and a favorable swing in working capital, including a significant decrease in accounts receivable in 2026. Net cash provided by financing activities was $2,032 in 2026 versus $75 in 2025, driven by increased cashflow from operations and proceeds from stock option exercises.FENNEC PHARMACEUTICALS INC., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →